Shares of Dendreon ( DNDN ) are soaring in pre market trading this morning hitting $9.00 at one point on no news. Well, I assume news was leaked because I cannot find DNDN news anywhere. What I think is happening is news has been confirmed that Dendreon will release data at the American Urological Association (AUA) conference at the end of the month. I'm sure some kind of news will be released later in the day stating this.
Click Here for my previous article on DNDN
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Showing posts with label provenge. Show all posts
Showing posts with label provenge. Show all posts
Monday, April 13, 2009
Friday, April 3, 2009
Dendreon DNDN Stock April 3 2009 4/3/09
Dendreon DNDN stock just ripped higher in the past hour and was really lighting up my screen with big buy orders. Not sure if there is some kind of news leak or if this is just one of those classic short squeezes we have been seeing all across the Stock Market lately.
Update: Provenge Receives " Late Breaking Status " - CNBC reports at 3PM EST
Massive Volume! DNDN stock went from $4.40 - $6.60 in about 30 minutes with a 4 million surge in volume.
DNDN Option trading has been bullish over the past Three days. Traders are betting that any day this month Dendreon will release positive clinical data and submit an application to receive FDA approval on their Cancer Drug Provenge.
Here are two great articles from Forbes:
Dendreon Closing In On Provenge Profits - The biotech firm gets closer to its drug hitting the market.
Dendreon Disclosure May Endanger Provenge Study - A decision to trumpet results from an unfinished study could come back to bite the drug maker.
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Update: Provenge Receives " Late Breaking Status " - CNBC reports at 3PM EST
Massive Volume! DNDN stock went from $4.40 - $6.60 in about 30 minutes with a 4 million surge in volume.
DNDN Option trading has been bullish over the past Three days. Traders are betting that any day this month Dendreon will release positive clinical data and submit an application to receive FDA approval on their Cancer Drug Provenge.
Here are two great articles from Forbes:
Dendreon Closing In On Provenge Profits - The biotech firm gets closer to its drug hitting the market.
Dendreon Disclosure May Endanger Provenge Study - A decision to trumpet results from an unfinished study could come back to bite the drug maker.
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Monday, October 6, 2008
Dendreon ( DNDN ) Provenge Study
Markets are tanking....but Dendreon DNDN shares are up 33% today because the company says they will release their final study on Provenge in about 8 months.
Dendreon Corp. (DNDN) said an interim analysis of a late-stage study shows its Provenge prostate-cancer therapy shows a 20% death-risk reduction compared to placebo.
President and Chief Executive Mitchell H. Gold said the findings, similar to those seen in prior phase 3 trials, should be finalized in mid-2009.
The study was ordered in May 2007 after the Food and Drug Administration requested more data to support the drug's proposed efficacy claim. An FDA advisory panel had voted Provenge had proven itself safe and effective.
Dendreon has been looking to get Provenge approved as a treatment for asymptomatic men with advanced prostate cancer who have stopped responding to hormone treatment. The drug is a departure from other approved cancer therapies in that it acts by stimulating the body's immune system to fight cancer using the patient's own white blood cells.
http://blackberrystocks.com/hotstocks.html
Dendreon Corp. (DNDN) said an interim analysis of a late-stage study shows its Provenge prostate-cancer therapy shows a 20% death-risk reduction compared to placebo.
President and Chief Executive Mitchell H. Gold said the findings, similar to those seen in prior phase 3 trials, should be finalized in mid-2009.
The study was ordered in May 2007 after the Food and Drug Administration requested more data to support the drug's proposed efficacy claim. An FDA advisory panel had voted Provenge had proven itself safe and effective.
Dendreon has been looking to get Provenge approved as a treatment for asymptomatic men with advanced prostate cancer who have stopped responding to hormone treatment. The drug is a departure from other approved cancer therapies in that it acts by stimulating the body's immune system to fight cancer using the patient's own white blood cells.
http://blackberrystocks.com/hotstocks.html
Subscribe to:
Posts (Atom)